New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTBCR, BCR, ISIS, ISIS, TRVN, TRVN, SGEN, SGEN, ONCS, ONCS, KBIO, KBIO, GNMK, GNMK, LXRX, LXRX, ACAD, ACAD, EXAM, EXAMNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
News For BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM From The Last 14 Days
Check below for free stories on BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
17:36 EDTBCRC.R. Bard raises FY14 EPS view to $8.25-$8.35 from $8.20-$8.30
Subscribe for More Information
17:34 EDTBCRC.R. Bard sees Q3 EPS $2.07-$2.11, consensus $2.09
Subscribe for More Information
16:25 EDTBCRC.R. Bard reports Q2 adjusted EPS $2.06, consensus $2.01
Subscribe for More Information
July 23, 2014
10:24 EDTTRVNTrevena management to meet with Jefferies
Subscribe for More Information
10:23 EDTTRVNTrevena management to meet with Needham
Subscribe for More Information
July 21, 2014
07:11 EDTONCSInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
July 15, 2014
09:03 EDTACADACADIA names Stephen Davis as EVP, CFO, Chief Business Officer
Subscribe for More Information
July 14, 2014
10:23 EDTTRVNTrevena management to meet with Needham
Meeting to be held in the Midwest on July 17 hosted by Needham.
07:04 EDTEXAMExamWorks management to meet with Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use